Janux Therapeutics, a preclinical biotech developing a novel class of T cell engagers for cancer, filed on Wednesday with the SEC to raise up to $100 million in an initial public offering.
Janux is developing next-generation therapeutics based on its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to better treat patients suffering from cancer. Its initial focus is on developing a novel class of T cell engagers, and its lead candidates are designed to target clinically validated drug targets. The company expects to submit at least two INDs by the end of 2022, initially seeking regulatory approval for its candidates as later lines of therapy in patients with cancer.
The La Jolla, CA-based company was founded in 2017 and plans to list on the Nasdaq under the symbol JANX. Janus Therapeutics filed confidentially on April 16, 2021. BofA Securities, Cowen, Evercore ISI, and H.C. Wainwright are the joint bookrunners on the deal. No pricing terms were disclosed.
